BRPI0414062B8 - uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv - Google Patents

uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv

Info

Publication number
BRPI0414062B8
BRPI0414062B8 BRPI0414062A BRPI0414062A BRPI0414062B8 BR PI0414062 B8 BRPI0414062 B8 BR PI0414062B8 BR PI0414062 A BRPI0414062 A BR PI0414062A BR PI0414062 A BRPI0414062 A BR PI0414062A BR PI0414062 B8 BRPI0414062 B8 BR PI0414062B8
Authority
BR
Brazil
Prior art keywords
treatment
cyclosporins
modified
hcv
disorders
Prior art date
Application number
BRPI0414062A
Other languages
English (en)
Portuguese (pt)
Inventor
Watashi Koichi
Shimotohno Kunitada
Hijikata Makoto
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414062A publication Critical patent/BRPI0414062A/pt
Publication of BRPI0414062B1 publication Critical patent/BRPI0414062B1/pt
Publication of BRPI0414062B8 publication Critical patent/BRPI0414062B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0414062A 2003-09-03 2004-09-02 uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv BRPI0414062B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
GB0320638.0 2003-09-03
PCT/EP2004/009804 WO2005021028A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Publications (3)

Publication Number Publication Date
BRPI0414062A BRPI0414062A (pt) 2006-10-24
BRPI0414062B1 BRPI0414062B1 (pt) 2019-06-25
BRPI0414062B8 true BRPI0414062B8 (pt) 2021-05-25

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414062A BRPI0414062B8 (pt) 2003-09-03 2004-09-02 uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv

Country Status (29)

Country Link
US (1) US7968518B2 (enExample)
EP (2) EP1797892B1 (enExample)
JP (1) JP4688806B2 (enExample)
KR (1) KR101116968B1 (enExample)
CN (1) CN1842343A (enExample)
AU (2) AU2004268382A1 (enExample)
BR (1) BRPI0414062B8 (enExample)
CA (1) CA2537137C (enExample)
CY (1) CY1110506T1 (enExample)
DE (1) DE602004022061D1 (enExample)
DK (1) DK1663287T3 (enExample)
ES (1) ES2328361T3 (enExample)
GB (1) GB0320638D0 (enExample)
HR (1) HRP20090535T1 (enExample)
IL (1) IL173909A (enExample)
IS (1) IS2917B (enExample)
MA (1) MA28032A1 (enExample)
MX (1) MXPA06002394A (enExample)
NO (1) NO20061479L (enExample)
NZ (1) NZ545495A (enExample)
PL (1) PL1663287T3 (enExample)
PT (1) PT1663287E (enExample)
RU (1) RU2389501C2 (enExample)
SG (1) SG149063A1 (enExample)
SI (1) SI1663287T1 (enExample)
TN (1) TNSN06071A1 (enExample)
TW (1) TWI342782B (enExample)
WO (1) WO2005021028A1 (enExample)
ZA (1) ZA200601550B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
ATE497775T1 (de) * 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006039163A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
CA2583494C (en) * 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
HRP20110169T1 (hr) 2004-10-01 2011-04-30 Debiopharm S.A. Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
ES2314731T3 (es) 2004-11-22 2009-03-16 Astellas Pharma Inc. Analogo de ciclosporina.
KR20070087624A (ko) * 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
CN101242842A (zh) * 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
DE602006020152D1 (de) * 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
PT1957518E (pt) * 2005-10-26 2016-02-26 Astellas Pharma Inc Novos compostos peptídicos cíclicos
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
CN101511357B (zh) 2006-05-19 2011-11-02 西尼克斯公司 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
EP2124992A2 (en) 2007-01-04 2009-12-02 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
KR20100017547A (ko) * 2007-05-02 2010-02-16 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US20130190223A1 (en) * 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
KR20110073473A (ko) * 2008-09-24 2011-06-29 아스텔라스세이야쿠 가부시키가이샤 펩티드 화합물 및 그의 제조 방법
CN102202679B (zh) * 2008-11-06 2014-05-07 帝柏奥研究制药有限公司 环十一缩酚酸肽化合物及其作为药物的用途
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
JP2013542206A (ja) 2010-10-05 2013-11-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
WO2012072655A1 (en) 2010-11-30 2012-06-07 Novartis Ag New treatments of hepatitis c virus infection
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
KR102011339B1 (ko) 2010-12-15 2019-08-16 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
RU2013148539A (ru) 2011-03-31 2015-05-10 Новартис Аг Алиспоривир для лечения инфекции вируса гепатита с
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
RU2013150344A (ru) 2011-04-13 2015-05-20 Новартис Аг Лечение инфекции вируса гепатита алисповиром
BR112014007247A2 (pt) 2011-09-27 2017-03-28 Novartis Ag alisporivir para o tratamento de infecção por vírus da hepatite c
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
EP3263587A1 (en) 2012-06-01 2018-01-03 Allergan, Inc. Cyclosporin a analogs
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
RU2016110247A (ru) 2013-08-26 2017-10-02 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения гепатита с
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
WO2022043678A1 (en) * 2020-08-24 2022-03-03 Nanomerics Limited Viral inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
DK0484281T4 (da) * 1990-11-02 2001-02-05 Novartis Ag Cyclosporiner
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
AU691225B2 (en) 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1319651T3 (da) 1997-04-04 2005-08-01 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
JP4232866B2 (ja) 2000-10-19 2009-03-04 有限会社 ケアティス 細胞障害抑制剤
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
PL367348A1 (en) 2001-03-26 2005-02-21 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
HRP20110169T1 (hr) 2004-10-01 2011-04-30 Debiopharm S.A. Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물

Also Published As

Publication number Publication date
DE602004022061D1 (de) 2009-08-27
IS2917B (is) 2014-12-15
IL173909A (en) 2011-03-31
WO2005021028A1 (en) 2005-03-10
US20070275884A1 (en) 2007-11-29
EP1797892A1 (en) 2007-06-20
BRPI0414062B1 (pt) 2019-06-25
RU2389501C2 (ru) 2010-05-20
HK1091732A1 (en) 2007-01-26
SG149063A1 (en) 2009-01-29
JP4688806B2 (ja) 2011-05-25
IL173909A0 (en) 2006-07-05
EP1797892B1 (en) 2013-10-23
BRPI0414062A (pt) 2006-10-24
PT1663287E (pt) 2009-09-03
PL1663287T3 (pl) 2009-12-31
NZ545495A (en) 2010-01-29
TW200524626A (en) 2005-08-01
RU2006110533A (ru) 2007-10-10
KR20060132798A (ko) 2006-12-22
AU2004268382A1 (en) 2005-03-10
EP1663287B1 (en) 2009-07-15
ZA200601550B (en) 2007-05-30
NO20061479L (no) 2006-06-02
TNSN06071A1 (en) 2007-10-03
KR101116968B1 (ko) 2012-03-14
TWI342782B (en) 2011-06-01
MXPA06002394A (es) 2006-06-20
EP1663287A1 (en) 2006-06-07
ES2328361T3 (es) 2009-11-12
US7968518B2 (en) 2011-06-28
HRP20090535T1 (hr) 2009-11-30
SI1663287T1 (sl) 2009-10-31
AU2008203031A1 (en) 2008-07-31
CA2537137C (en) 2013-05-28
CY1110506T1 (el) 2015-04-29
MA28032A1 (fr) 2006-07-03
GB0320638D0 (en) 2003-10-01
AU2008203031B2 (en) 2011-04-07
DK1663287T3 (da) 2009-11-09
CA2537137A1 (en) 2005-03-10
JP2007504260A (ja) 2007-03-01
IS8371A (is) 2006-03-24
CN1842343A (zh) 2006-10-04

Similar Documents

Publication Publication Date Title
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
TNSN07240A1 (en) Compounds for flaviviridae treatment
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
DOP2009000094A (es) Inhibidores de la proteasa ns3 del hcv
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
BRPI0519345A2 (pt) composiÇço para tratamento do hcv
BRPI0508217A (pt) cetamidas com p4's cìclico como inibidores de ns3 serina protease de vìrus de hepatite c
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
UA85559C2 (en) Aminobenzophenone compounds
TN2010000074A1 (en) Cyclic depsipeptides
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
BRPI0415123A (pt) uso de l-butilftalida e respectiva composição farmacêutica
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.